Alto Neuroscience Inc
(ANRO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -29,447 | -13,417 | -36,305 | -25,088 | -15,947 |
| Depreciation Amortization | 210 | 97 | 373 | 261 | 198 |
| Accounts receivable | N/A | N/A | N/A | 325 | N/A |
| Accounts payable and accrued liabilities | 869 | 1,120 | -632 | 149 | 790 |
| Other Working Capital | 1,175 | -255 | -698 | 458 | -376 |
| Other Operating Activity | 4,516 | 1,472 | 3,814 | 1,971 | 1,176 |
| Operating Cash Flow | $-22,677 | $-10,983 | $-33,448 | $-21,924 | $-14,159 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -564 | -224 | -470 | -118 | -75 |
| Investing Cash Flow | $-564 | $-224 | $-470 | $-118 | $-75 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 137,650 | 137,589 | 181 | 152 | 43 |
| Other Financing Activity | -3,325 | -3,030 | 67,949 | 24,846 | 24,906 |
| Financing Cash Flow | $134,325 | $134,559 | $68,130 | $24,998 | $24,949 |
| Exchange Rate Effect | -10 | -5 | -8 | -12 | -30 |
| Beginning Cash Position | 82,548 | 82,548 | 48,344 | 48,344 | 48,344 |
| End Cash Position | 193,622 | 205,895 | 82,548 | 51,288 | 59,029 |
| Net Cash Flow | $111,074 | $123,347 | $34,204 | $2,944 | $10,685 |
| Free Cash Flow | |||||
| Operating Cash Flow | -22,677 | -10,983 | -33,448 | -21,924 | -14,159 |
| Capital Expenditure | -564 | -224 | -470 | -118 | -75 |
| Free Cash Flow | -23,241 | -11,207 | -33,918 | -22,042 | -14,234 |